JAMA network open · 2026
Standard Intraoperative Fluid Practices During the 2024 Intravenous Fluid Shortage.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hopstein Noah, Borngaesser Felix, Droege Lorenz, Khandaker Rafi, Kiyatkin Michael E, Rinke Michael L, Semczuk Peter P, Weiss Jeffrey M, Kolmel Nicholas, Condoleo Mark, Wongtangman Karuna, Bordbar Jahantighi Ali, Karaye Ibraheem M, Kotek Tomer, Aguirre-Alarcon Adela M, Rippel Constance, Straetz Dorothee S, Siciliano Michele C, Hallick Jason, Suleiman Aiman M, Racine Andrew D, Eikermann Matthias
Аннотация
IMPORTANCE: A nationwide intravenous fluid shortage in 2024 prompted hospitals to substantially reduce intraoperative crystalloid administration, creating a natural experiment to examine standard intraoperative fluid practices. The clinical consequences of such abrupt reductions in fluid use remain unclear.
OBJECTIVE: To evaluate the associations among a marked reduction in intraoperative crystalloid administration, perioperative outcomes, and costs of care.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted from September 2 to December 31, 2024, across a hospital network in the Bronx, New York, comprising adults undergoing surgery at 9 hospitals of different acuity levels.
EXPOSURE: The exposure was the implementation of a hospital-wide intervention aimed at reducing intraoperative intravenous crystalloid administration.
MAIN OUTCOMES AND MEASURES: Primary outcomes included change in intraoperative crystalloid administration. Additional outcomes included intraoperative hypotension, urine output, urinary catheter utilization, hospital readmissions, postoperative acute kidney injury, length of stay, and costs of care.
RESULTS: A total of 38 976 patients (mean [SD], age 55.7 [19.8] years; 21 944 [56.3%] female), including 12 026 (30.9%) before and 26 950 (69.1%) during implementation of a fluid reduction bundle, were included in the study. The implementation of the fluid reduction bundle was associated with a 75.2% lower intraoperative crystalloid administration (adjusted exponentiated β coefficient [eβ], 0.25; 95% CI, 0.24-0.26; P < .001). The intervention was associated with lower urine output (adjusted eβ, 0.91; 95% CI, 0.85-0.96; P = .002), reduced urinary catheter utilization (adjusted relative risk [ARR], 0.87; 95% CI, 0.83-0.92; P < .001), and fewer hospital readmissions (ARR, 0.82; 95% CI, 0.75-0.89; P < .001). There were no meaningful differences in intraoperative hypotension (adjusted eβ, 1.01; 95% CI, 1.00-1.02; P = .07), postoperative acute kidney injury (ARR, 0.97; 95% CI, 0.86-1.09; P = .58), or costs of care (adjusted eβ, 1.00; 95% CI, 0.98-1.01; P = .46).
CONCLUSIONS AND RELEVANCE: In this cohort study's natural experiment, grossly reduced intraoperative crystalloid fluid administration was associated with lower urine output, reduced urinary catheter use, and fewer hospital readmissions, without worse patient-centered outcomes. These results challenge standard intraoperative fluid practices.
OBJECTIVE: To evaluate the associations among a marked reduction in intraoperative crystalloid administration, perioperative outcomes, and costs of care.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted from September 2 to December 31, 2024, across a hospital network in the Bronx, New York, comprising adults undergoing surgery at 9 hospitals of different acuity levels.
EXPOSURE: The exposure was the implementation of a hospital-wide intervention aimed at reducing intraoperative intravenous crystalloid administration.
MAIN OUTCOMES AND MEASURES: Primary outcomes included change in intraoperative crystalloid administration. Additional outcomes included intraoperative hypotension, urine output, urinary catheter utilization, hospital readmissions, postoperative acute kidney injury, length of stay, and costs of care.
RESULTS: A total of 38 976 patients (mean [SD], age 55.7 [19.8] years; 21 944 [56.3%] female), including 12 026 (30.9%) before and 26 950 (69.1%) during implementation of a fluid reduction bundle, were included in the study. The implementation of the fluid reduction bundle was associated with a 75.2% lower intraoperative crystalloid administration (adjusted exponentiated β coefficient [eβ], 0.25; 95% CI, 0.24-0.26; P < .001). The intervention was associated with lower urine output (adjusted eβ, 0.91; 95% CI, 0.85-0.96; P = .002), reduced urinary catheter utilization (adjusted relative risk [ARR], 0.87; 95% CI, 0.83-0.92; P < .001), and fewer hospital readmissions (ARR, 0.82; 95% CI, 0.75-0.89; P < .001). There were no meaningful differences in intraoperative hypotension (adjusted eβ, 1.01; 95% CI, 1.00-1.02; P = .07), postoperative acute kidney injury (ARR, 0.97; 95% CI, 0.86-1.09; P = .58), or costs of care (adjusted eβ, 1.00; 95% CI, 0.98-1.01; P = .46).
CONCLUSIONS AND RELEVANCE: In this cohort study's natural experiment, grossly reduced intraoperative crystalloid fluid administration was associated with lower urine output, reduced urinary catheter use, and fewer hospital readmissions, without worse patient-centered outcomes. These results challenge standard intraoperative fluid practices.